期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

卵巢癌生物标志物研究的现代进展 被引量：3

下载PDF
导出
摘要 卵巢癌是妇女中最普通的一种恶性肿瘤。由于卵巢癌临床症状含糊不清,大多数病人是在晚期阶段诊断出的。本文概述了用血清生物标志物对卵巢癌早期诊断及疾病进程监测的当前进展。
作者 王继贵
机构地区 中南大学湘雅二医院检验科
出处 《实验与检验医学》 CAS 2013年第6期515-517,共3页 Experimental and Laboratory Medicine
关键词 卵巢癌 生物标志物 检测
分类号 R737.31 [医药卫生—肿瘤] R730.43 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Lokshin AE. The quest for ovarian cancer screening biomarkers:are we on the right road. [J]. Int J Gynecol Cancer, 2012 22(suppll):S35-40.
  • 2YurkovetskyZ, Skates S, Lomakin A,et al. Development of a multi-marker assay for early detection of ovarian cancer [J]. J Clin Oncol,2010, 28(13):2159-2166.
  • 3ChenVW, Ruiz B, Killeen JL, et al. Pathology and classification ofovarian tumors [J]. Cancer, 2003, 97(10 suppl):2631 -2642.
  • 4CramerDW, Bast Jr RC, Berg CD,et al. Ovarian cancer biomarkerperformace' in prostate, lung colorectal and ovarian cancerscreening trial specimens [J]. Cancer Prev Res (Phila) 2011, 4(3):365-374.
  • 5LutzAM, Willmann JK, Drescher CW,et al. Early diagnosis of o-varian carcinoma: is a solution in sight. [J]. Radiology 2011, 259(2): 329-345.
  • 6RustinGJ, Vergote I, Eisenhauer E,et al. Definition for responseand progression in ovarian cancer clinical trials incorporating RE-CIST 1.1 and CAI25 agreed by the Gynecological Cancer Inter-group (GCIG) [JJ. Int J Gynecol Cancer, 2011,21(2):419-423.
  • 7PratA, Parera M, Peralta S,et al. Nadir CA125 concentration in thenormal range as an independent prognostic factor for optimallytreated advanced epithelial ovarian cancer [J], Ann Oncol, 2008,19(2):327-331.
  • 8DrapkinR, von Horsten HH, Lin Y,et al. Human epididymis pro-tein 4 (HE4) is a secreted glycoprotein that is overexpressed byserous and endometrioid ovarian carcinomas [J]. Cancer Res,2005,65(6): 2162-2169.
  • 9EscuderoJM, Auge JM, Filella X,et al. Comparison of serum hu-man epididymis protein 4with cancer antigen 125 as a tumor mark-er in patients with malignant and nonmalignant diseases [J]. ClinChem, 2011, 57(11):1534-1544.
  • 10AnastasiE, Marchei (;G,Viggiani V,et al. HE4: a new potentialearly biomarker for the recurrence of ovarian cancer [J]. TumourBiol, 2010,31(2):113-119.

同被引文献39

  • 1李山,秦雪,何卫华.血清CA125在卵巢癌诊断中的价值及文献评价[J].中华检验医学杂志,2005,28(2):209-211. 被引量：37
  • 2马培奇.抗肿瘤新药替吉奥钾研究进展[J].中国医药导刊,2007,9(6):499-502. 被引量：54
  • 3Drescher CW, Shah C, Thorpe J, et al. Longitudinal screening al- gorithm that incorporates change over time in CA125 levels identi- fies ovarian cancer earlier than a single -threshold rule[ J]. J Clin Oneol, 2013, 31(3): 387-392.
  • 4Charafe - Jauffret E, Ginestier C, Bertucci F, et al. ALDH1 - pos- itive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program[J]. Cancer Res, 2013, 73(24): 7290-7300.
  • 5Ataseven H, Oztiirk ZA, Arhan M, et al. Cancer antigen 125 lev- els in inflammatory bowel diseases[ J]. J Clin Lab Anal, 2009, 23 (4) : 244 -248.
  • 6NeeshamD. Ovarian cancer screening [ J ]. Aust Fam Physician, 2007, 36(3) : 126 -128.
  • 7Bouanene H, Miled A. Tumor Marker CA125: biochemical and molecular properties [ J ]. Bull Cancer, 2009, 96 ( 5 ) : 597 - 601.
  • 8Kawakami Y, Matsushita M, Ueda R, et al. Immunotherapy targe- ting cancer stem cells[J]. Nihon Rinsho, 2012, 70(12) : 2142 - 2146.
  • 9Kim SK, Kim H, Lee DH, et al. Reversing the Intractable Nature of Pancreatic Cancer by Selectively Targeting ALDH - High, Thera- py - Resistant Cancer Cells [J]. PLoS One, 2013, 8 (10) : e78130.
  • 10Xu Z, Shen Z, Shi L, et al. Aldehyde dehydrogenase 1 expression correlated with malignant potential of oral lichen planus [ J ]. Ann Diagn Pathol, 2013,17(5) : 408 -411.

引证文献3

二级引证文献16

实验与检验医学
2013年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部